Is vascular endothelial growth factor a missing link between hypertension and inflammation?

Hypertension

Volumn 44, Issue 3, 2004, Pages 253-254

  Morishita, Ryuichi ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BLOOD PRESSURE; EDITORIAL; GENE TARGETING; GENE TRANSFER; HEART HYPERTROPHY; HYPERTENSION; INFLAMMATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; ANTI-INFLAMMATORY AGENTS; EXTRACELLULAR MATRIX PROTEINS; GENES, LETHAL; HUMANS; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; RATS; TRANSFECTION; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444246849     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000138689.29876.b3     Document Type: Editorial

References (13)

1. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:945-2951.
2. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857-861.
3. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 1998;15:342-349.
4. Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens. 2002;16:539-547.
5. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: Role of ET(A) receptors. Hypertension. 2002;39:679-684.
6. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Loffler BM, Ganten D, Schneider W, Haller H, Luft FC. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000;36:282-290.
7. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004;44:264-270.
8. Baumgartner I, Isner JM. Somatic gene therapy in the cardiovascular system. Annu Rev Physiol. 2001;63:427-450.
9. Morishita R, Ogihara T. In vivo evaluation of in vitro hypothesis using "gain or loss" of function: functional analysis of renin-angiotensin system. Am J Hypertens. 1998;11:507-513.
10. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KI, Moore MW. Heterozygous embryonic lethality induced by targeted in activation of the VEGF gene. Nature. 1996;380:439-442.
11. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and leathality in embryos lacking a single VEGF allele. Nature. 1996;380:435-442.
12. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
13. Fong GH, Rossant J, Gertsenstein M, and Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.